YouSigma- the web's most extensive resource for information
$6.99 Domain Names at Network SolutionsĀ®!
Takeda Pharmaceutical Co. Ltd. (SWOT Analysis)

Go to Home Page

Tell your friend about this WebSite!

Download PDF Version!

“SWOT is an acronym for the internal Strengths and Weaknesses of a firm and the environmental Opportunities and Threats facing that firm. SWOT analysis is a widely used technique through which managers create a quick overview of a company’s strategic situation. The technique is based on the assumption that an effective strategy derives from a sound “fit” between a firm’s internal resources (strengths and weaknesses) and its external situation (opportunities and threats). A good fit maximizes a firm’s strengths and opportunities and minimizes its weaknesses and threats. Accurately applied, this simple assumption has powerful implications for the design of a successful strategy.”

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical (Takeda), the largest pharmaceutical company in Japan, is engaged in the discovery, development, manufacture and marketing a range of pharmaceutical products such as enzymes, seratrodast, allergic drugs, vaccines, antihypertensive drugs and other pharmaceuticals. The company also manufactures and markets other products including photographic and inorganic chemicals, vitamins, test reagents and clinical diagnostics. Takeda markets its in-house ethical drugs in around 90 countries. Takeda primarily operates in Japan. It is headquartered in Osaka, Japan and employs about 15,700 people.

Strengths, Weaknesses, Opportunities and Threats (SWOT)

Location of Factor

TYPE OF FACTOR

Favorable

Unfavorable

Internal

Strengths

  • Profitable position as the largest drug maker in Japan
  • Blockbuster offerings spanning four therapeutic disciplines
  • Strategically placed in endocrinology market
  • Strong US positioning
  • Abundance of drugs in late-stage development

Weaknesses

  • Heavy dependency on its four blockbuster therapeutics
  • All four of Takeda’s blockbusters will see patent expiries by 2012

External

Opportunities

  • Actos could capitalize of the collapse of its principal competitor, GSK’s Avandia
  • Scope to enhance its biologic positioning, particularly in monoclonal antibody development

Threats

  • Japanese healthcare reforms encourage generic prescribing
  • Increasing penetration of Japanese market by western players
underline
About YouSigma Please Donate Using PayPal, to help us Develop Content
Copyright and Disclaimer
Loading
underline
underline
Try a free sample Destiny Reading! Executive Openings! $80,000 to $500,000+
"Takeda Pharmaceutical Co. Ltd. (SWOT Analysis)";